Biotime News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.12.17	Additional Renevia Data From the Successful Pivotal Trial Was Presented at the IFATS Conference (Businesswire)
30.11.17	Data from BioTime’s Renevia® Program to Be Presented at IFATS Conference (Businesswire)
15.11.17	BioTime Presents Updated OpRegen® Phase I/IIa Trial Data at AAO (Businesswire)
13.11.17	BioTime to Participate in Upcoming Conferences (Businesswire)
09.11.17	BioTime Reports Third Quarter Results and Recent Corporate Accomplishments (Businesswire)
08.11.17	AgeX Therapeutics VP of New Technology Discovery Aubrey de Grey to Serve on Aging & Longevity Panel at FT Global Pharmaceutical and Biotechnology Conference, November 9-10 in London (Businesswire)
02.11.17	BioTime nimmt an der Jefferies 2017 London Healthcare Conference teil (Businesswire)
02.11.17	BioTime to Participate in the Jefferies 2017 London Healthcare Conference (Businesswire)
26.07.17	Positive Data IGNITEs TTPH, MDCO Makes A Good TANGO, Wait Continues For EGRX (RTTNews)
26.06.17	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating BioTime, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors (PR Newswire)
19.06.17	Hadasit Bio-Holdings (HBL) and BioTime Complete Shares Swap Transaction in Cellcure Neurosciences (PR Newswire)
15.06.17	ALDX Down But Not Out, BTX On Track, MNK Exploring New Use For Acthar (RTTNews)
09.06.17	D-Day For CHRS, ENDO Pained, FDA Lifts Clinical Hold On INO's VGX-3100 Trial (RTTNews)
24.05.17	How These Biotech Stocks are Faring? -- Idera Pharma, BioTime, RXi Pharma, and Tenax Therapeutics (PR Newswire)
04.04.17	Regenerative Technology Innovations in the Medical Market (PR Newswire)
17.03.17	AVXS Abuzz, PTCT Slammed For Emflaza Deal, INNL Scouts For Buyer (RTTNews)
21.11.16	Positive erste Daten aus BioTimes pivotaler Studie zu Renevia auf IFATS-Konferenz präsentiert (Businesswire)
18.11.16	Positive Early Data From BioTime’s Renevia Pivotal Trial Presented at IFATS Meeting (Businesswire)
20.10.16	First Patient Cohort Data From BioTime’s OpRegen® Clinical Trial in Dry-AMD to Be Presented at ISOPT Clinical Symposium on December 2, 2016 (Businesswire)
26.04.16	BioTime Co-CEO Dr. Michael West Presents at Biomedical Innovation for Healthy Longevity, International Conference (Businesswire)
05.04.16	BioTime Co-CEO Dr. Michael West to Present at Stem Cells in Drug Discovery 2016 in Cambridge, UK (Businesswire)
30.09.15	Heraeus Medical GmbH and BioTime Subsidiary OrthoCyte Corporation Enter Into Exclusive Worldwide Development and Licensing Agreements (Businesswire)
24.02.15	BioTime Announces First Patient Treated in Pivotal Clinical Trial of Renevia™ for HIV-Associated Lipoatrophy (Businesswire)
15.09.14	BioTime, Inc.’s Subsidiary OncoCyte Corporation and Abcodia to Collaborate on Breast Cancer Diagnostic Development (Businesswire)
11.09.14	BioTime Subsidiary, Asterias Biotherapeutics, and Cancer Research UK and Cancer Research Technology Partner for Clinical Trial of Immunotherapy Vaccine for Lung Cancer (Businesswire)
28.05.14	BioTime Receives ISO 13485 Certification for Medical Devices (Businesswire)
13.01.14	BioTime Reports Results of Clinical Safety Trial of Renevia™ (Businesswire)
25.11.13	BioTime CEO Dr. Michael West to Present at 11th Annual Commercial Translation of Regenerative Medicine Conference (Businesswire)
28.10.13	BioTime Reports Interim Results on Renevia™ Clinical Safety Trial (Businesswire)
08.08.13	PDL BioPharma Announces Second Quarter 2013 Financial Results (PR Newswire)
10.01.13	BioTime Submits Protocol for Initiation of Human Clinical Trials of Renevia™ in Europe (Businesswire)
15.11.12	BioTime Announces Non-Binding Letter of Intent with Geron Regarding Stem Cell Assets (Businesswire)
30.05.12	BioTime CEO Dr. Michael West to Present at the Jefferies 2012 Global Healthcare Conference (Businesswire)
23.05.12	BioTime and Subsidiary LifeMap Sciences, Inc. Announce Release of GeneCards® Version 3.08 (Businesswire)
22.05.12	BioTime and Subsidiary LifeMap Sciences, Inc. Announce Agreement to Market MalaCards - A Database of Human Diseases (Businesswire)
21.05.12	BioTime Completes Merger of XenneX, Inc. into LifeMap Sciences, Inc. (Businesswire)
14.05.12	HyStem®-C Demonstrated Effective when Formulated with Human Heart Cells and Transplanted in an Animal Model of Heart Disease (Businesswire)
23.04.12	BioTime’s Subsidiary LifeMap Sciences, Inc. Presents Update on Product Development (Businesswire)
23.04.12	BioTime’s Subsidiary ReCyte Therapeutics, Inc. Provides Update on Preclinical Development of Vascular Progenitors for the Treatment of Age-Related Vascular Disease (Businesswire)
23.04.12	BioTime and its Subsidiary OrthoCyte Corporation Provides Update on Preclinical Development of OTX-CP07 (Businesswire)
23.04.12	BioTime’s Subsidiary OncoCyte Corporation Provides Update on PanC-DxTM, and Related Diagnostic Products (Businesswire)
23.04.12	BioTime’s Subsidiary Cell Cure Neurosciences, Ltd. Provides Update on OpRegen® Product Development (Businesswire)
23.04.12	BioTime Provides Update on ReneviaTM Product Development (Businesswire)
23.04.12	BioTime Demonstrates Efficient Method for the Manufacture of Cartilage-Producing Cells from Human Embryonic Stem Cells (Businesswire)
18.04.12	BioTime CEO Michael D. West to Present at the Future Leaders in the Biotech Industry Conference (Businesswire)
16.04.12	BioTime CEO Michael D. West to Present at the 8th GTC Stem Cell Summit 2012 (Businesswire)
12.04.12	BioTime Board of Directors Forms Science and Technology Committee (Businesswire)
22.03.12	BioTime’s Subsidiary OncoCyte Corporation Provides an Update on the Development of the Novel Pan-Cancer Diagnostic Product PanC-DxTM (Businesswire)
21.03.12	BioTime CEO Michael D. West to Present at 2012 Maxim Group Growth Conference (Businesswire)
14.03.12	BioTime Announces Fourth Quarter and Fiscal Year End 2011 Financial Results and Recent Corporate Accomplishments (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Novartis	95.58	1.90 %	K V
Logitech Intl	91.48	1.35 %	K V
Part Grp Hldg	1’393.00	1.20 %	K V
Roche Hldg G	286.00	0.28 %	K V
Sonova Hldg	319.20	0.16 %	K V
Swiss Re	139.40	-0.50 %	K V
Zurich Insur Gr	553.80	-0.54 %	K V
Kuehne+Nagel Int	207.60	-0.76 %	K V
Lonza Grp	582.00	-1.49 %	K V
Nestle	77.48	-1.53 %	K V

Nachrichten zu Biotime IncShs

Aktien Top/Flop

Meistgelesene Nachrichten